All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RLYB211
Therapeutic Area: Immunology Product Name: RLYB211
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
The Phase 1/2 study is a single-blind, placebo-controlled proof-of-concept study designed to establish the dose of RLYB211 that will rapidly clear HPA-1a positive platelets transfused to HPA-1a negative healthy male participants.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RLYB211
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020
Details:
Róisín Armstrong, PhD. Dr. Armstrong, a seasoned drug developer, will head the development of the Company’s lead program, RLYB211. RLYB211, a plasma-derived hyperimmune globulin, is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RLYB211
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Pivotal bioVenture Partners
Deal Size: $145.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 19, 2020
Details:
Proceeds from the financing will be used to advance Rallybio’s current portfolio of product candidates targeting devastating rare diseases, including its lead program, RLYB211. RLYB211 is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia.